Seneste forsøg

EudraCT Number: 2007-003913-15 Sponsor Protocol Number: ANTRAG01 Start Date:
Sponsor Name: Medical University Innsbruck
Full Title: Wirkung von Oxcarbazepin (Trileptal) auf den Kortikosteroid-Metabolismus - Pilotstudie
Medical condition: Oxcarbazepin, a widely-used antiepileptic treatment is evaluated with respect to Cortisol-degradation. Young adults and adults with oxcarbazepine monotherapy since at least 6 months and temporal lo...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adolescents, Under 18, Adults Gender: Male
Trial protocol: AT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2010-022785-27 Sponsor Protocol Number: Q4882g Start Date:
Sponsor Name: Genentech, Inc.
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO Evaluate the efficacy, RESPONSE DURATION and safety OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDI...
Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU)
Disease: Version SOC Term Classification Code Term Level
12.1 10021247 Idiopathic urticaria LLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: FR (Ongoing) DE (Completed) DK (Completed) IT (Completed) ES (Ongoing)
Trial results: View results
EudraCT Number: 2014-004806-14 Sponsor Protocol Number: TKS-2014-001 Start Date:
Sponsor Name: Therakos, Inc.
Full Title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute ...
Medical condition: Acute graft-versus-host disease (aGvHD)
Disease: Version SOC Term Classification Code Term Level
20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: DE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) AT (Completed)
Trial results: View results
EudraCT Number: 2018-004878-99 Sponsor Protocol Number: INCB84344-102 Start Date:
Sponsor Name: Incyte Biosciences International Sàrl
Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants
Medical condition: Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000830 Acute leukaemia PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028549 Myeloid leukaemia PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028553 Myeloid leukaemia, chronic LLT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028552 Myeloid leukaemia, acute LLT
20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) FR (Ongoing) ES (Ongoing) DE (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-006597-23 Sponsor Protocol Number: UX143-CL301 Start Date:
Sponsor Name: Ultragenyx Pharmaceutical Inc.
Full Title: A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta.
Medical condition: Osteogenesis imperfecta (OI)
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: FR (Ongoing) DK (Prematurely Ended) DE (Ongoing) IT (Ongoing) PL (Ongoing) PT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2017-004851-22 Sponsor Protocol Number: B7451015 Start Date:
Sponsor Name: Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001, U.S.A.
Full Title: A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with m...
Medical condition: Moderate to severe atopic dermatitis
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10003639 Atopic dermatitis LLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) CZ (Ongoing) HU (Trial now transitioned) PL (Ongoing) NL (Ongoing) BG (Ongoing) BE (Ongoing) LV (Ongoing) ES (Ongoing) SK (Completed) FR (Completed) AT (Completed) SE (Prematurely Ended) IT (Ongoing) FI (Ongoing) RO (Ongoing)
Trial results: (No results available)
EudraCT Number: 2018-004828-11 Sponsor Protocol Number: RECHMPL18_0038_prom_7574 Start Date:
Sponsor Name: University Hospital of Montpellier
Full Title: Phosphodiesterase-type 5 inhibitors in adult and adolescent patients with univentricular heart disease: a multi-center, randomized, double blind phase III study
Medical condition: adult and adolescent patients with univentricular heart diseases and pulmonary arterial pressure
Disease: Version SOC Term Classification Code Term Level
Population Age: Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: FR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2017-003220-78 Sponsor Protocol Number: I8B-MC-ITSA Start Date:
Sponsor Name: Eli Lilly and Company
Full Title: A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus
Medical condition: Diabetes Mellitus, Type 1
Disease: Version SOC Term Classification Code Term Level
20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2014-002442-45 Sponsor Protocol Number: AXAFA-AFNET5 Start Date:
Sponsor Name: Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)]
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.
Medical condition: Atrial fibrillation catheter ablation
Disease: Version SOC Term Classification Code Term Level
19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
19.0 10007541 - Cardiac disorders 10071667 Persistent atrial fibrillation LLT
19.0 10007541 - Cardiac disorders 10003661 Atrial fibrillation paroxysmal LLT
19.0 10007541 - Cardiac disorders 10066582 Recurrent atrial fibrillation LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed)
Trial results: (No results available)
EudraCT Number: 2006-006907-35 Sponsor Protocol Number: SP915 Start Date:
Sponsor Name: Schwarz Biosciences GmbH
Full Title: Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTI...
Medical condition: Parkinson's disease
Disease: Version SOC Term Classification Code Term Level
9.1 10061536 Parkinson's disease LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) HU (Completed) IT (Completed) GB (Completed) AT (Prematurely Ended)
Trial results: View results

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner